Related Experiment Video
Updated: Apr 10, 2026
08:58
Matrix-assisted Autologous Chondrocyte Transplantation for Remodeling and Repair of Chondral Defects in a Rabbit Model
Published on: May 21, 2013
14.8K
Regulatory Challenges for Cartilage Repair Technologies
Kevin B McGowan1, Glenn Stiegman1
1Musculoskeletal Clinical Regulatory Advisers, Washington, DC, USA.
Cartilage
|June 13, 2015
Summary
Navigating the Food and Drug Administration (FDA) approval process for cartilage repair products is complex. Strategic planning of clinical trials and regulatory pathways is crucial for timely market access.
Area of Science:
- Orthopedics
- Biomaterials Science
- Regulatory Science
Background:
- Limited Food and Drug Administration (FDA)-approved treatments are available for focal cartilage and osteochondral lesions in the U.S.
- Product developers encounter significant hurdles in obtaining FDA marketing approval for cartilage repair innovations.
Purpose of the Study:
- To delineate the essential steps for FDA application and approval of novel cartilage repair products.
- To provide insights into the regulatory landscape for cartilage repair therapies.
Main Methods:
- Review of FDA Guidance Documents, FDA Panel Meetings, scientific organization recommendations, and clinicaltrials.gov.
- Analysis of current FDA and scientific community perspectives on the regulatory process for cartilage repair.
Main Results:
- Cartilage repair products may be approved as medical devices, drugs, or biologics, influencing regulatory strategies.
- FDA guidance offers general requirements, necessitating careful design of study populations, comparators, and endpoints.
- Early consideration of regulatory strategy and manufacturing validation is vital for efficient product approval.
Conclusions:
- The regulatory pathway for cartilage repair therapies is challenging and lengthy.
- Meticulous clinical trial planning and attention to detail can expedite product market entry, saving time and resources.
